The two companies are combining the latest in HOS and Mass Spec technologies to help scientists improve the safety, stability, and effectiveness of biotherapeutics. The state-of-the art structural biology workflow starts with the GenNext Flash Oxidation (Fox®) Protein Footprinting System performing covalent labeling of biotherapeutic products. Then, the ZenoTOF 7600 system from SCIEX is employed for mass spectrometry analysis. Finally, GenNext’s FoxWare^® Data Processing Software is leveraged to execute high resolution HOS data analysis.

Together, GenNext and Emery Pharma deliver best-in-class pharmaceutical functional and structural analysis for allosteric and monoclonal antibody therapeutics. For clients seeking contract research, the GenNext/Emery Pharma team will generate data-rich insights to help them accelerate the approval of biotherapeutics and to develop safer, more effective, and less expensive therapeutic products.